Replimune's PDUFA Milestone Approaches Amidst 72% Stock Decline
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Replimune Group Inc (Nasdaq: REPL) is a clinical-stage biotechnology company headquartered in Woburn, Massachusetts. The company develops oncolytic immunotherapies designed to trigger systemic anti-tumor immune responses across a broad range of solid tumors. As of July 22, 2025, REPL shares closed at $3.40, reflecting a 72.41% decline year-to-date, on a trading volume of 15,205,712 shares.
| Metric | Value |
|---|---|
| Share price (Jul 22) | $3.40 |
| Year-to-date change | ‑72.41% |
| Trading volume | 15,205,712 |
| Exchange | NASDAQ |
| Ticker | REPL |
Corporate Structure
According to its LinkedIn profile, Replimune employs between 201 and 500 people. The company was founded in 2015 and has its U.S. headquarters at 500 Unicorn Park Drive, Woburn, MA. Manufacturing facilities are located at 33 New York Ave., Framingham, MA, and a site in the United Kingdom supports production and research activities.
Oncolytic immunotherapy by National Cancer Institute
Recent Developments
In July 2025, Replimune reached full enrollment in its IGNYTE trial of RP1 plus nivolumab in advanced melanoma, with a PDUFA date set for July 22, 2025. A confirmatory IGNYTE-3 study is currently enrolling, and another IGNYTE cohort is evaluating the combination in non-melanoma skin cancers, including cases refractory to anti-PD-1 therapy. The ARTACUS trial is investigating RP1 monotherapy in organ transplant recipients with skin cancer. Data from the IGNYTE trial in anti-PD-1-failed melanoma were published in the Journal of Clinical Oncology in July 2025.
On May 23, 2025, Replimune filed a Form S-3 registration statement under the Securities Act of 1933, indicating plans to raise additional capital. On July 22, 2025, the company filed a Current Report on Form 8-K, which typically discloses material events, management changes, and risk factor updates.
Financial and Strategic Analysis
Replimune’s share price has declined 72.41% through July 22, 2025, consistent with the financial pressures often faced by clinical-stage biotech firms. The May 23 S-3 filing highlights a need for financing to support ongoing trials and research and development programs. Replimune retains full commercial rights to RP1 while collaborating with Bristol-Myers Squibb for the supply of nivolumab. The company evaluates RP1 as both a monotherapy and in combination regimens to potentially expand its market presence across various solid tumor indications.
Market Position and Industry Context
Replimune operates within the oncolytic immunotherapy segment of biotechnology research, a sector characterized by competition from established immuno-oncology firms and emerging treatment modalities. The PDUFA decision for RP1 plus nivolumab on July 22, 2025, may be a significant milestone for the company. Regulatory outcomes and trial results may influence Replimune's ability to establish its products in treatment protocols for melanoma and skin cancers, while advancements in broader solid tumor studies could further define its position in the market.
TL;DR
On July 22, 2025, Replimune's RP1 + nivolumab combination in advanced melanoma reached a PDUFA decision date following complete enrollment in the IGNYTE trial. Confirmatory IGNYTE-3 and non-melanoma cohorts continue to enroll, and the ARTACUS monotherapy study is active. The stock has dropped 72.41% year-to-date, and a May 23 S-3 filing indicates planned capital raises to fund further clinical development.